

BLA 761452

BLA APPROVAL

Accord BioPharma, Inc.
Attention: Sabita Nair, RAC, ASQ-CPGP
Vice President - Regulatory Affairs
8041 Arco Corporate Drive
Suite 200
Raleigh, NC 27617

Dear Sabita Nair:

Please refer to your biologics license application (BLA) received May 16, 2025, and your amendments, submitted under section 351(k) of the Public Health Service Act for Immgolis and Immgolis Intri (golimumab-sldi) injection.

This BLA seeks licensure of:

- Immgolis (golimumab-sldi) 50 mg/0.5 mL (100 mg/mL) injection for subcutaneous use in a single-dose prefilled syringe (PFS) as biosimilar to and interchangeable with US-Simponi (golimumab) injection 50 mg/0.5 mL (100 mg/mL) for subcutaneous use in a PFS,
- Immgolis (golimumab-sldi) 100 mg/mL injection for subcutaneous use in a PFS as biosimilar to and interchangeable with US-Simponi (golimumab) 100 mg/mL injection for subcutaneous use in a PFS, and
- Immgolis Intri (golimumab-sldi) 50 mg/4 mL (12.5 mg/mL) injection for intravenous use in a single-dose vial as biosimilar to and interchangeable with US-Simponi Aria (golimumab) 50 mg/4 mL (12.5 mg/mL) injection for intravenous use in a single dose vial.

LICENSING

We have approved your BLA for Immgolis and Immgolis Intri (golimumab-sldi) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, Immgolis and Immgolis Intri under your existing Department of Health and Human Services U.S. License No. 2105. Immgolis and Immgolis Intri are indicated for:

Immgolis is indicated for:

- Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate

- Treatment of adult patients with moderately to severely active ulcerative colitis (UC)

Immgolis Intri is indicated for:

- Treatment of adult patients with moderately to severely active RA in combination with methotrexate

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture golimumab-sldi drug substance and the final formulated drug product at (b) (4)

(b) (4) You may label your products with the proprietary names Immgolis and Immgolis Intri, and market it in 50 mg/0.5 mL and 100 mg/1 mL single-dose prefilled syringes (Immgolis), and 50 mg/4 mL single-dose vials (Immgolis Intri).

DATING PERIOD

The dating period for Immgolis and Immgolis Intri shall be 24 months from the date of manufacture when stored at $5 \pm 3^{\circ}\text{C}$, protected from light, and may be stored up to 15 days at room temperature up to 25°C in original carton. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at $-(b) (4) \pm (b) (4)^{\circ}\text{C}$.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Immgolis and Immgolis Intri to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Immgolis and Immgolis Intri, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

FIRST INTERCHANGEABLE EXCLUSIVITY

Section 351(k)(6) of the PHS Act provides:

The Secretary shall not make approval as an interchangeable biological product effective with respect to an application submitted under this subsection that relies on the same reference product for which a prior biological product has received a determination of interchangeability for any condition of use, until the earlier of—

- (A) 1 year after the first commercial marketing of the first interchangeable biosimilar biological product to be approved as interchangeable for that reference product;
- (B) 18 months after—
 - (i) a final court decision on all patents in suit in an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or (ii) the dismissal with or without prejudice of an action instituted under subsection (l)(6) against the applicant that submitted the application for the first approved interchangeable biosimilar biological product; or
- (C)
 - (i) 42 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has been sued under subsection (l)(6) and such litigation is still ongoing within such 42-month period; or
 - (ii) 18 months after approval of the first interchangeable biosimilar biological product if the applicant that submitted such application has not been sued under subsection (l)(6).

For purposes of this paragraph, the term “final court decision” means a final decision of a court from which no appeal (other than a petition to the United States Supreme Court for a writ of certiorari) has been or can be taken and the term “first interchangeable biosimilar biological product” means any interchangeable biosimilar biological product that is approved on the first day on which such a product is approved as interchangeable with the reference product.

FDA has determined that the following products qualify as first interchangeable biosimilar biological products for purposes of section 351(k)(6) of the PHS Act:

- Immogolis (golimumab-sldi) injection, 50 mg/0.5 mL (100 mg/mL) for subcutaneous use in a PFS
- Immogolis (golimumab-sldi) injection, 100 mg/mL for subcutaneous use in a PFS

- Immgolis Intri (golimumab-sldi) injection, 50 mg/4 mL (12.5 mg/mL) for intravenous use in a single-dose vial

The expiration date of any first interchangeable exclusivity for these products has yet to be determined.

For each interchangeable biosimilar biological product approved by this letter, submit a general correspondence to this 351(k) BLA informing the Agency of the date of the first commercial marketing within 30 days of such date. Submit a duplicate copy of the correspondence via email to PurpleBook@fda.hhs.gov. As a reminder and in addition to the above request, section 506I(b) of the Federal Food, Drug, and Cosmetic Act requires BLA holders to provide a written notification to FDA within 180 days of the date of approval of a drug if that drug will not be available for sale within 180 days of the date of approval.

Please submit a general correspondence to this 351(k) BLA within 30 days of this approval informing the Agency of **any action implicating this BLA instituted under section 351(l)(6) of the PHS Act**. If no action implicating this BLA has been instituted under section 351(l)(6), please inform the Agency accordingly within 30 days of this approval. If an action implicating this BLA has been instituted under section 351(l)(6), then inform the Agency of the date of any final court decision (as defined in section 351(k)(6) of the PHS Act) on all patents in suit in any action implicating this BLA instituted under section 351(l)(6) of the PHS Act, or the date of dismissal with or without prejudice of any action implicating this BLA instituted under section 351(l)(6), within 30 days of such date or within 30 days of this approval if such date occurred prior to approval. If any action implicating this BLA instituted under section 351(l)(6) is still ongoing at the time of this approval, submit a general correspondence informing the Agency accordingly within 30 days of this approval. Submit a duplicate copy of the correspondence(s) via email to PurpleBook@fda.hhs.gov.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

FULL PRESCRIBING INFORMATION (Immgolis)

- **12.3 Pharmacokinetics/Absorption:** Corrected (b) (4) to "mL".
- **14.2 Adult Ulcerative Colitis/**Table 5: corrected spelling and footnote marker to "remission^a".

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling **and** carton and container labeling submitted on March 10, 2026, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761452.**” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

U.S. Food and Drug Administration

Silver Spring, MD 20993

www.fda.gov

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.

If you have questions, contact Anh-Thy Ly, Project Manager, at 240-402-1001 or Anh-Thy.Ly@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Raj Nair, MD
Division Director
Division of Rheumatology and Transplant
Medicine
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use (Immgolis)
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RAJ NAIR
05/15/2026 01:27:42 PM